MSB 1.60% $1.54 mesoblast limited

Ann: MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase, page-2

  1. 741 Posts.
    lightbulb Created with Sketch. 34

    In 2019, Mesoblast Ltd  (MSB) plans to work diligently with the U.S. Food and Drug Administration (FDA) to submit a rolling Biologics License Application for use of remestemcel-L in treating acute graft versus host disease (aGVHD) in children, and will execute on the product candidate’s market access and commercialization strategy  


    http://crweworld.com/article/news-provided-by-globenewswire/930707/mesoblast-highlights-2019-key-priorities-for-its-leading-cellular-medicines-pipeline-at-biotech-showcase-in-san-francisco
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.54
Change
-0.025(1.60%)
Mkt cap ! $780.3M
Open High Low Value Volume
$1.55 $1.56 $1.54 $720.1K 465.3K

Buyers (Bids)

No. Vol. Price($)
2 1601 $1.54
 

Sellers (Offers)

Price($) Vol. No.
$1.55 1186 3
View Market Depth
Last update - 12.06pm 24/04/2019 (20 minute delay) ?
(live)
Last
$1.55
  Change
-0.025 ( 0.52 %)
Open High Low Volume
$1.55 $1.56 $1.54 30150
Last updated 12.24pm 24/04/2019 (live) ?
MSB (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.